Development and characterization of gemcitabine-resistant pancreatic tumor cells

Annals of Surgical Oncology

Volumn 14, Issue 12, 2007, Pages 3629-3637

  Shah, Ami N ^a   Summy, Justin M ^a   Zhang, Jing ^a   Park, Serk In ^a   Parikh, Nila U ^a   Gallick, Gary E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

c Met; Cancer stem cells; EMT; Gemcitabine chemoresistance; Pancreatic cancer

Indexed keywords

BETA CATENIN; CD24 ANTIGEN; EPITHELIAL MEMBRANE ANTIGEN; GEMCITABINE; HERMES ANTIGEN; UVOMORULIN; VIMENTIN;

ARTICLE; CELL ACTIVATION; CELL ADHESION; CELL CULTURE; CELL INVASION; CELL MIGRATION; CELL TRANSFORMATION; CONTROLLED STUDY; DEVELOPMENT; FIBROBLAST; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE TEST; PANCREAS TUMOR; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PSEUDOPODIUM; TUMOR CELL;

ANTIGENS, CD44; ANTIMETABOLITES, ANTINEOPLASTIC; BETA CATENIN; CADHERINS; CELL ADHESION; CELL MOVEMENT; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; EPITHELIUM; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; MEMBRANE PROTEINS; MESODERM; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MET; TUMOR CELLS, CULTURED;

EID: 36349006961     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-007-9583-5     Document Type: Article

References (35)

1. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13
2. Moore MJ, Hamm J, Dancey J, et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: A phase III trial of the national cancer institute of Canada clinical trials group. J Clin Oncol 2003;17:3296-302
3. Yang AD, Fan F, Camp ER, et al. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res 2006;12:4147-53
4. Hiscox S, Jiang WG, Obermeier K, et al. Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation. Int J Cancer 2006;118:290-301
5. Hiscox S, Morgan L, Barrow D, et al. Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839). Clin Exp Metastasis 2004;21:201-12
6. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2:442-54
7. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial mesenchymal transitions. Nat Rev Mol Cell Biol 2006;7:131-42
8. Boyer B, Valles AM, Edme N. Induction and regulation of epithelial to mesenchymal transitions. Biochem Pharm 2000;60:1091-9
9. Savagner P. Leaving the neighborhood: molecular mechanisms involved during epithelial to mesenchymal transition. BioEssays 2001;23:912-23
10. Grotegut S, von Schweinitz D, Christofori G, Lehembre F. Hepatocyte growth factor induces cell scattering through MAPK/Egr-1-mediated upregulation of Snail. EMBO J 2006;25:3534-45
11. Jeffers M, Rong S, Vande Woude GF. Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network. Mol Cell Biol 1996;16:1115-25
12. Bladt F, Riethmacher D, Isenmann S, Aguzzi A, Birchmeier C. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 1995;376:768-71
13. Schmidt C, Bladt F, Goedecke S, et al. Scatter factor/hepatocyte growth factor is essential for liver development. Nature 1995;373:699-702
14. Matsumoto K, Nakamura T. HGF: its organotrophic role and therapeutic potential. Ciba Found Symp 1997;212:198-211
15. Miyazawa K, Shimomura T, Naka D, Kitamura N. Proteolytic activation of hepatocyte growth factor in response to tissue injury. J Biol Chem 1994;269:8966-70
16. Jiang W, Hiscox S, Matsumoto K, Nakamura T. Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. Crit Rev Oncol Hematol 1999;29:209-48
17. Herynk MH, Tsan R, Radinsky R, Gallick GE. Activation of c-Met in colorectal carcinoma cells leads to constitutive association of tyrosine-phosphorylated beta-catenin. Clin Exp Metastasis 2003;20:291-300
18. Gray MJ, Zhang J, Ellis LM, et al. HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependant hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene 2005;24:3110-20
19. Summy JM, Trevino JG, Baker CH, et al. c-Src regulates constitutive and EGF-mediated VEGF expression in pancreatic tumor cells through activation of phosphatidyl inosityol 3-kinase and p38 MAPK. Pancreas 2005;31:263-74
20. Rasola A, Fassetta M, De Bacco F, D'Alessandro L, Gramaglia D, Di Renzo MF, Comoglio PM. A positive feedback loop between hepatocyte growth factor receptor and beta-catenin sustains colorectal cancer cell invasive growth. Oncogene 2007;26:1078-87
21. Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res 2007;67:1030-7
22. La Porta CA. Drug resistance in melanoma: new perspectives. Curr Med Chem 2007;14:387-91
23. Donnenberg VS, Donnenberg AD. Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J Clin Pharmacol 2005;45:872-7
24. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29
25. Nakano Y, Tanno S, Koizumi K, et al. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br J Cancer 2007;96:457-63
26. Shah AN, Gallick GE. Src, chemoresistance and epithelial to mesenchymal transition: are they related? Anticancer Drugs 2007;18:371-5
27. Shibamoto S, Hayakawa M, Takeuchi K, et al. Tyrosine phosphorylation of beta-catenin and plakoglobin enhanced by hepatocyte growth factor and epidermal growth factor in human carcinoma cells. Cell Adhes Commun 1994;1:295-305
28. Hiscox S, Jiang WG. Association of the HGF/SF receptor, c-met, with the cell-surface adhesion molecule, E-cadherin, and catenins in human tumor cells. Biochem Biophys Res Commun 1999;261:406-11
29. Monga SP, Mars WM, Pediaditakis P, et al. Hepatocyte growth factor induces Wnt-independent nuclear translocation of beta-catenin after Met-beta-catenin dissociation in hepatocytes. Cancer Res 2002;62:2064-71
30. Yang J, Mani SA, Donaher JL, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004;117:927-39
31. Kang Y, Massague J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 2004;118:277-9
32. Howe LR, Watanabe O, Leonard J, Brown AM. Twist is up-regulated in response to Wnt1 and inhibits mouse mammary cell differentiation. Cancer Res 2003;63:1906-13
33. Hoek K, Rimm DL, Williams KR, et al. Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res 2004;64:5270-82
34. Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD, Wang LH. Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res 2007;67:1979-87
35. Minard MM, Herynk MH, Collard JG, Gallick GE. The guanine nucleotide exchange factor Tiam1 increases colon carcinoma growth at metastatic sites in an orthotopic nude mouse model. Oncogene 2005; 24:2568-2573